CaffeineNCT06606652
Caffeine, Resistance Exercise and EMG
A study testing Caffeine in people with Caffeine, run by University of Alcala at 1 site in Spain.
Trial summary
Introduction: Several studies have evaluated and confirmed the ergogenic effects of acute caffeine intake on sports performance. However, some studies suggest that this effect predominantly occurs in large muscle groups, potentially due to increased skeletal muscle electrical activity. Read more about this study
- Who is it for?
- Ages 18 to 35 yearsHealthy volunteers can take part
- Conditions the study is for
- Caffeine
- What is being tested?
- Caffeine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 12 participants
- Where
- 1 siteSpain
- Study dates
- 1 Sep 2023to 30 Apr 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age between 18 and 35 years.
- Body Mass Index (BMI) \< 25 kg/m².
- Resistance-trained individuals (more than 2 years of structured training).
- Healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from exercising.
- Participants must be able to perform the tests described in the following section.
Who cannot join
- History of neuromuscular diseases, heart disease, or conditions that may affect liver or muscle metabolism.
- Use of drugs, stimulants, or sports supplements that could interfere with the dietary supplement used in the study.
- Sedentary habits (less than 150 minutes/week of moderate exercise).
- Having undergone prolonged periods of physical inactivity in the 6 months prior to the study.
- Engaging in strenuous exercise within 48 hours prior to the tests.
- Failure to replicate the same food intake on both experimental days.
- Consumption of caffeine or any other stimulant after 6 pm on the day before the tests, to avoid headaches, discomfort, or lethargy in regular caffeine consumers.
Trial locations and contacts
1 site in 1 country.
Spain1 site
Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá
Alcalá de Henares, Madrid, 28805
About this study
Official title: Effect of Acute Caffeine Intake on Muscle Electrical Activity and Muscular Strength, Power, and Endurance Performance
Introduction: Several studies have evaluated and confirmed the ergogenic effects of acute caffeine intake on sports performance. However, some studies suggest that this effect predominantly occurs in large muscle groups, potentially due to increased skeletal muscle electrical activity.
Objectives: This study aims to evaluate the acute effects of caffeine intake on strength, power, muscle endurance, and muscle electrical activity in young adults. It will also analyze the influence of circadian rhythms (morning vs. afternoon) on exercise performance (bench press vs. squat).
Methods: Twelve healthy, physically active participants will be recruited for the study. Using a triple-blind, crossover, randomized, and controlled design, participants will ingest either caffeine (3 mg/kg body mass) or a placebo (maltodextrin, 3 mg/kg) 60 minutes before the trial. Muscular strength, power, and endurance performance will then be assessed through 1RM tests, and at 25%, 50%, 75%, and 90% of 1RM, along with muscle endurance tests at 65% of 1RM, for both squat and bench press exercises. EMG will be used to measure skeletal muscle electrical activity during the tests. The experimental sessions will be conducted in the morning (8:00 am to 10:00 am) and the afternoon (4:30 pm to 6:30 pm).
- Conditions
- Caffeine
- Being tested
- Caffeine, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CaffeineDietary supplement
Acute caffeine intake (3 mg/kg)
PlaceboDietary supplement
Acute placebo intake (3 mg/kg of maltodextrin)
| Study group | Role | What they receive |
|---|---|---|
| Caffeine - Morning | Experimental | Not described Receives: Dietary Supplement: Caffeine |
| Caffeine - Evening | Experimental | Not described Receives: Dietary Supplement: Caffeine |
| Placebo - Morning | Placebo comparator | Not described Receives: Dietary Supplement: Placebo |
| Placebo - Evening | Placebo comparator | Not described Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean velocity at different %1RM
Measuring bar mean velocity desplacement during bench press and back squat exercises.
Measured: Through study completion, an average of 4 weeks
Peak velocity at different %1RM
Measuring bar peak velocity and time to reach peak velocity of bar desplacement during bench press and back squat exercises.
Measured: Through study completion, an average of 4 weeks
Mean power output at different %1RM
Measuring during bench press and back squat exercises.
Measured: Through study completion, an average of 4 weeks
Peak power output and time to reach peak power output at different %1RM
Measuring during bench press and back squat exercises.
Measured: Through study completion, an average of 4 weeks
Number of repetitions performed in 1 set at 65%1RM until task failure
Measured: Through study completion, an average of 4 weeks
Bar velocity deplacement performed in 1 set at 65%1RM until task failure
In bench press and back squat exercises
Measured: Through study completion, an average of 4 weeks
Power output generated in 1 set at 65%1RM until task failure
In bench press and back squat exercise
Measured: Through study completion, an average of 4 weeks
Muscle electrical activity (EMG).
Root-mean-square (RMS) and maximal voluntary contraction (MVC) from pectoralis major and triceps (bench press) and from rectus femoris and vastus lateralis (Back squat).
Measured: Through study completion, an average of 4 weeks
Secondary outcomes (2)
Mood state (tension, depression, anger, vigor, fatigue and confusion)
Participants graded a set of 29 items related to the mood on a Likert scale from 0 (not at all) to 4 (extremely) in reply to the question: How do you feel at this moment? To assess six scales: tension, depression, anger, vigor, fatigue and confusion.
Measured: Through study completion, an average of 4 weeks
Adverse effects
perception of power, endurance, energy and exertion, as well as heart, muscular and gastrointestinal discomfort.
Measured: Through study completion, an average of 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Sep 2024
- Study start1 Sep 2023
- Primary completion30 Apr 2024
- Study completion30 Apr 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CaffeineStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 12 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Alcala
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Alberto Pérez-López, University of Alcala
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06606652
- Sponsor's protocol ID
- CEIP/2023/4/093_2
- Status last verified
- Sep 2024
- First submitted
- 9 Sep 2024
- Last updated
- 23 Sep 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 23 Sep 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Acute Caffeine Intake on Muscle Electrical Activity and Muscular Strength, Power, and Endurance Performance
- ClinicalTrials.gov ID
- NCT06606652
- Acronym / sponsor ID
- CEIP/2023/4/093_2
- Conditions
- Caffeine
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 12 participants (actual)
- Lead sponsor
- University of AlcalaUniversity, hospital or other
- Study start
- 1 Sep 2023 (actual)
- Primary completion
- 30 Apr 2024 (actual)
- Study completion
- 30 Apr 2024 (actual)
- First posted
- 23 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Introduction: Several studies have evaluated and confirmed the ergogenic effects of acute caffeine intake on sports performance. However, some studies suggest that this effect predominantly occurs in large muscle groups, potentially due to increased skeletal muscle electrical activity.
Objectives: This study aims to evaluate the acute effects of caffeine intake on strength, power, muscle endurance, and muscle electrical activity in young adults. It will also analyze the influence of circadian rhythms (morning vs. afternoon) on exercise performance (bench press vs. squat).
Methods: Twelve healthy, physically active participants will be recruited for the study. Using a triple-blind, crossover, randomized, and controlled design, participants will ingest either caffeine (3 mg/kg body mass) or a placebo (maltodextrin, 3 mg/kg) 60 minutes before the trial. Muscular strength, power, and endurance performance will then be assessed through 1RM tests, and at 25%, 50%, 75%, and 90% of 1RM, along with muscle endurance tests at 65% of 1RM, for both squat and bench press exercises. EMG will be used to measure skeletal muscle electrical activity during the tests. The experimental sessions will be conducted in the morning (8:00 am to 10:00 am) and the afternoon (4:30 pm to 6:30 pm).
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Caffeine - Morning | Experimental | Dietary Supplement: Caffeine |
| Caffeine - Evening | Experimental | Dietary Supplement: Caffeine |
| Placebo - Morning | Placebo comparator | Dietary Supplement: Placebo |
| Placebo - Evening | Placebo comparator | Dietary Supplement: Placebo |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Age between 18 and 35 years.
- Body Mass Index (BMI) \< 25 kg/m².
- Resistance-trained individuals (more than 2 years of structured training).
- Healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from exercising.
- Participants must be able to perform the tests described in the following section.
Key exclusion criteria (7 listed)
- History of neuromuscular diseases, heart disease, or conditions that may affect liver or muscle metabolism.
- Use of drugs, stimulants, or sports supplements that could interfere with the dietary supplement used in the study.
- Sedentary habits (less than 150 minutes/week of moderate exercise).
- Having undergone prolonged periods of physical inactivity in the 6 months prior to the study.
- Engaging in strenuous exercise within 48 hours prior to the tests.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CaffeineAcute caffeine intake (3 mg/kg) | Dietary supplement | Caffeine - Evening, Caffeine - Morning |
| PlaceboAcute placebo intake (3 mg/kg of maltodextrin) | Dietary supplement | Placebo - Evening, Placebo - Morning |
Primary outcome
Mean velocity at different %1RM
Time frame: Through study completion, an average of 4 weeks
Measuring bar mean velocity desplacement during bench press and back squat exercises.
Peak velocity at different %1RM
Time frame: Through study completion, an average of 4 weeks
Measuring bar peak velocity and time to reach peak velocity of bar desplacement during bench press and back squat exercises.
Mean power output at different %1RM
Time frame: Through study completion, an average of 4 weeks
Measuring during bench press and back squat exercises.
Peak power output and time to reach peak power output at different %1RM
Time frame: Through study completion, an average of 4 weeks
Measuring during bench press and back squat exercises.
Number of repetitions performed in 1 set at 65%1RM until task failure
Time frame: Through study completion, an average of 4 weeks
Bar velocity deplacement performed in 1 set at 65%1RM until task failure
Time frame: Through study completion, an average of 4 weeks
In bench press and back squat exercises
Power output generated in 1 set at 65%1RM until task failure
Time frame: Through study completion, an average of 4 weeks
In bench press and back squat exercise
Muscle electrical activity (EMG).
Time frame: Through study completion, an average of 4 weeks
Root-mean-square (RMS) and maximal voluntary contraction (MVC) from pectoralis major and triceps (bench press) and from rectus femoris and vastus lateralis (Back squat).
2 secondary outcomes
Mood state (tension, depression, anger, vigor, fatigue and confusion)
Time frame: Through study completion, an average of 4 weeks
Adverse effects
Time frame: Through study completion, an average of 4 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Sep 2024.
- Individual participant dataSharing planned: Yes
Related trials for Caffeine
Active, not recruiting
The REVIVE-PEEP Trial: Positive End-expiratory Pressure Versus Sham Valve/Zero End-expiratory Pressure in Cardiopulmonary Resuscitation During Manual Ventilation to Improve Neurological Outcomes at Discharge in Adult Patients Suffering an Out-of-hospital Cardiac Arrest
Cardiac Arrest, Out-Of-Hospital
Recruiting
The Effect of Short-term Supplementation of OliPhenolia® on Fat Oxidation
Healthy
Active, not recruitingPhase 4
A Study to See if an Energy Drink With Caffeine and Green Tea Increases Fat Burning When Exercising
Exercise
Not yet recruitingPhase 2
CAffeine Use in Prolonged Oxygen Use in meConium aspIration Syndrome in Neonatal Outcomes (CAPUCINO)
Meconium Aspiration Syndrome
Recruiting
A Clinical Trial to Evaluate the Effects of Adrenal Adapt on Sleep Quality, Daytime Energy, Stress Resilience, and Cognitive Performance.
Improves Daytime Energy Levels, Reduces Afternoon Energy Crashes and Midday Fatigue
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Caffeine in people with Caffeine, run by University of Alcala at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Sep 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean velocity at different %1RM (time frame: Through study completion, an average of 4 weeks). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2024.